BTI's IPOXYN data on traumatic shock and ischemia to be presented at XIIIth MGH symposium

Jul 29 2011

Boston Therapeutics, Inc. (BTI), a public company registered with the SEC and a developer of diabetes therapeutics, announced today that experiments performed in the laboratory of Massachusetts General Hospital (MGH) faculty member Warren M. Zapol, MD, Emeritus Anesthetist-in-Chief and Director of the MGH Anesthesia Center for Critical Care Research, on BTI's new oxygen carrier for traumatic shock and ischemia, IPOXYN^TM, will be presented at the "XIII International Symposium on Blood Substitutes and Oxygen Therapeutics" to be held July 27^th-29^th at MGH. Data will be presented in a talk by Binglan Yu, Ph.D., Instructor in Anesthesia, MGH, and will include hemodynamic data in a diabetic mouse model infused with IPOXYN^TM.

"We are very pleased to have recently signed a Material Transfer Agreement with MGH to continue the animal testing of IPOXYN^TM," said Ken Tassey, President, Boston Therapeutics. "IPOXYN^TM is an oxygen carrier designed for critical limb ischemia associated with diabetes and we are excited to have this new data presented here today. We are preparing to scale-up our manufacturing of IPOXYN^TM and our meetings with the FDA have shown positive support" said Tassey.

IPOXYN^TM is a glyco-protein oxygen carrier designed for hypoxic conditions such as limb ischemia, hemorrhagic shock and other conditions requiring oxygen transport to hypoxic tissues. Using a proprietary carbohydrate chemistry platform, BTI has engineered a uniquely-stabilized oxygen carrier that has been shown to perfuse and selectively off-load oxygen in ischemic capillaries where the limb vasculature is damaged. IPOXYN^TM is intended as a user-ready, intravenous solution to target acute hypoxic conditions that have a great unmet medical need.

"These new data from Drs. Yu and Zapol will add to our existing research on IPOXYN^TM," said Joan Sellers, Ph.D., Chief Technology Officer, Boston Therapeutics. "In addition to lower limb ischemia, we anticipate the future indications for IPOXYN^TM to include traumatic blood loss, anemia, hemorrhagic shock, as well as blood supplementation during surgery. We believe that IPOXYN^TM will be a first-in-class drug upon FDA approval and we look forward to our continued collaboration with Dr. Zapol's laboratory at MGH," said Sellers.